Valneva SE

Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases. The company focuses on providing first-, best-, or only-in-class vaccine solutions. Valneva currently markets three proprietary travel vaccines. Its clinical portfolio includes vaccine candidates designed to provide preventative solutions for diseases with high unmet need. The company's pipeline includes VLA15, a Lyme disease vaccine candidate in advanced clinical development, which is being developed in partnership with Pfizer. VLA15 is a Phase 3 vaccine candidate targeting Borrelia, the bacterium that causes Lyme disease, and is the only vaccine candidate against Lyme disease currently undergoing late-stage clinical trials. Pfizer and Valneva are executing the Phase 3 field efficacy trial for VLA15, called VALOR (Vaccine Against Lyme for Outdoor Recreationists). Vaccinations were completed in July 2025, and participants were monitored for Lyme disease cases until the end of 2025. VLA15 targets the six most prevalent serotypes of Borrelia in the Northern Hemisphere. Approximately 476,000 people are diagnosed with Lyme disease each year in the United States, and at least 132,000 cases occur annually in Europe. Valneva's pipeline also includes the world's most clinically advanced tetravalent Shigella vaccine candidate, under development in collaboration with LimmaTech Biologics AG. Additionally, VLA1553 is a single-dose, live-attenuated vaccine against chikungunya, currently marketed outside the United States under the brand name IXCHIQ. This product continues to be evaluated in ongoing Phase 3/4 clinical trials, including post-marketing studies.